Physician profile
Andrew Bennett Wright
NPI 1306462775
$2,148.32
in general payments reported to CMS, 2019-2025
28 companies · $967 in 2025
The $967 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $132 · 2023: $194 · 2024: $856 · 2025: $967.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,016.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,016.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $736.19 | 2023-2025 | Vraylar |
| Astrazeneca Pharmaceuticals Lp | $132.66 | 2022-2025 | Breztri, Farxiga |
| E.R. Squibb & Sons, L.L.C. | $118.13 | 2022 | |
| Radius Health, INC. | $109.32 | 2024-2025 | Tymlos |
| Neurocrine Biosciences, INC. | $96.20 | 2025 | |
| Viiv Healthcare Company | $92.96 | 2025 | |
| Novo Nordisk INC | $73.30 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $72.43 | 2023-2025 | |
| Lilly USA, LLC | $68.61 | 2024 | Jardiance |
| Teva Pharmaceuticals USA, INC. | $62.44 | 2023-2025 | Austedo Xr, Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $54.93 | 2025 | Caplyta |
| Novartis Pharmaceuticals Corporation | $54.73 | 2024-2025 | |
| Amgen INC. | $52.16 | 2023-2025 | Evenity, Prolia, Prolia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.01 | 2024 | Jardiance |
| Pfizer INC. | $49.69 | 2023-2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $38.74 | 2024 | Freestyle Libre 3 |
| Mylan Specialty L.P. | $35.50 | 2023 | Yupelri |
| Verona Pharma, INC. | $31.19 | 2025 | Ohtuvayre |
| Otsuka America Pharmaceutical, INC. | $30.06 | 2025 | Rexulti |
| Irhythm Technologies, INC. | $28.17 | 2024 | Zio Xt Patch, Zio Monitor |
| Becton, Dickinson and Company | $26.68 | 2024 | Bard Urinary Drainage Bag |
| Axsome Therapeutics, INC. | $23.19 | 2025 | Auvelity |
| Lundbeck LLC | $21.56 | 2025 | Rexulti |
| Viatris Specialty LLC | $21.44 | 2025 | Yupelri |
| Paratek Pharmaceuticals, INC. | $19.71 | 2023 | Nuzyra |
| Tolmar, INC. | $17.56 | 2025 | Eligard |
| Janssen Pharmaceuticals, INC | $14.54 | 2024 | Spravato |
| Glaxosmithkline, LLC. | $14.22 | 2025 | Shingrix, Arexvy, Penmenvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Wright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.